Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
Returns on capital
Solid Biosciences Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-96.8%
avg -44.5%
ROIC
-89.1%
avg -67.9%
ROA
-75.0%
avg -55.9%
Analysis
ROA is currently the strongest return metric at -75.0% versus its period average of -55.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Alexander G. Cumbo | President, Chief Executive Officer & Director | USD 1.11M | 55 | — | — |
David Tyronne Howton Jr. | Chief Operating Officer & Secretary | USD 791.72K | 54 | — | — |
Gabriel Brooks | Chief Medical Officer | USD 772.73K | 49 | 97.24K | 0.12% |
Kevin Tan | Chief Financial Officer & Treasurer | USD 607.18K | 48 | 99.42K | 0.13% |
Ian F. Smith | Executive Chair | USD 75K | 60 | 3.44K | <0.01% |
Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer & Director | USD 40K | 52 | 150.00K | 0.19% |
Annie Ganot | Co-Founder & Vice President of Patient Advocacy | — | — | — | — |
Nicole Anderson | Senior Director of Investor Relations & Corporate Communications | — | — | — | — |
Paul Herzich | Chief Technology Officer | — | 48 | 72.64K | 0.09% |
Jessie Hanrahan | Chief Regulatory & Preclinical Operations Officer | — | 50 | 74.32K | 0.10% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 19, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
28
$2.68M
Net Transaction Value
−$2.68M
Net selling
Most Active
Brooks Gabriel
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 19, 26Oct 19, 2026 | Brooks Gabriel Direct | Sell | $24.6K$24,581.88 |
| Feb 18, 26Feb 18, 2026 | Cumbo Alexander Direct | Sell | $96.9K$96,923.01 |
| Feb 18, 26Feb 18, 2026 | Hanrahan Jessie Direct | Sell | $24.1K$24,073.52 |
| Feb 18, 26Feb 18, 2026 | Tan Kevin Direct | Sell | $31.5K$31,469.11 |
| Feb 18, 26Feb 18, 2026 | Brooks Gabriel Direct | Sell | $0$0.00 |
| Feb 18, 26Feb 18, 2026 | Howton David T Direct | Sell | $43.5K$43,494.23 |
| Feb 18, 26Feb 18, 2026 | Herzich Paul Direct | Sell | $21.1K$21,057.05 |
| Feb 18, 26Feb 18, 2026 | Ganot Ilan Indirect | Sell | $15.5K$15,478.33 |
| Feb 4, 26Feb 4, 2026 | Cumbo Alexander Direct | Sell | $315.1K$315,092.65 |
| Feb 4, 26Feb 4, 2026 | Ganot Ilan Indirect | Sell | $46.4K$46,413.89 |
1–10 of 28
Summary
Insiders reported 0 buys worth $0.00 and 28 sells worth $2.68M over the last 12 months. That adds up to net selling of $2.68M. Brooks Gabriel was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Solid Biosciences Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about SLDB's management, answered from reported figures.
Who manages SLDB?
Solid Biosciences Inc. (SLDB) lists 10 active executives. The top listed executive is David Tyronne Howton Jr., Chief Operating Officer & Secretary.
Are SLDB insiders buying or selling?
Recent insider activity shows net buying of $47.78M.
Continue the stock analysis
Jump to another research area for this company.